Agios Pharmaceuticals, Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-04-02$35.20 RISE2026-04-27$24.43 PEAK2026-05-28$30.42 56d | -30.6% 25d | Missed | Missed | — | — | +24.5% 31d | Missed |
DROP2025-11-18$45.49 RISE2026-02-06$26.53 PEAK2026-04-02$35.20 135d | -41.7% 80d | Missed | Missed | — | — | +32.7% 55d | Missed |
DROP2025-11-18$45.49 RISE2025-12-19$24.46 PEAK2026-02-24$30.39 98d | -46.2% 31d | Missed | Missed | — | — | +24.2% 67d | Missed |
DROP2025-11-18$45.49 RISE2025-11-19$22.34 PEAK2025-11-28$29.20 10d | -50.9% 1d | Missed | Missed | — | — | +30.7% 9d | Missed |
DROP2024-12-06$61.64 RISE2025-04-08$24.53 PEAK2025-07-03$36.07 209d | -60.2% 123d | Missed | Missed | — | — | +47.0% 86d | Missed |
DROP2024-07-23$49.72 RISE2024-10-08$40.50 PEAK2024-12-06$61.64 136d | -18.5% 77d | Missed | Missed | — | — | +52.2% 59d | Missed |
DROP2024-06-05$48.83 RISE2024-07-08$41.19 PEAK2024-07-23$49.72 48d | -15.6% 33d | Missed | Missed | — | — | +20.7% 15d | Missed |
DROP2024-02-27$34.81 RISE2024-04-05$27.55 PEAK2024-06-05$48.83 99d | -20.9% 38d | Missed | Missed | — | — | +77.2% 61d | Missed |
DROP2023-09-13$27.25 RISE2024-01-18$21.32 PEAK2024-02-27$34.81 167d | -21.8% 127d | Missed | Missed | — | — | +63.3% 40d | Missed |
DROP2023-06-28$29.19 RISE2023-10-27$19.97 PEAK2024-01-08$24.45 194d | -31.6% 121d | Missed | Missed | — | — | +22.4% 73d | Missed |
DROP2022-12-02$31.52 RISE2023-04-12$21.38 PEAK2023-06-28$29.19 208d | -32.2% 131d | Missed | Missed | — | — | +36.5% 77d | Missed |
DROP2022-09-09$34.14 RISE2022-12-28$26.26 PEAK2023-02-07$30.93 151d | -23.1% 110d | Missed | Missed | — | — | +17.8% 41d | Missed |
DROP2022-09-09$34.14 RISE2022-10-24$25.69 PEAK2022-12-02$31.52 84d | -24.8% 45d | Missed | Missed | — | — | +22.7% 39d | Missed |
DROP2022-04-04$31.42 RISE2022-07-26$19.51 PEAK2022-09-09$34.14 158d | -37.9% 113d | Missed | Missed | — | — | +75.0% 45d | Missed |
DROP2022-03-02$32.26 RISE2022-06-14$17.06 PEAK2022-09-09$34.14 191d | -47.1% 104d | Missed | Missed | — | — | +100.1% 87d | Missed |
1–15 / 23 1 / 2 | |||||||
Agios Pharmaceuticals, Inc. a Sell amid tebapivat setback & tougher PK activator competition; see risks, SCD catalysts, and cash runway. Click for an AGIO update.
Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Shares drop following disappointing mid-stage trial outcomeAgios Pharmaceuticals (NASDAQ:AGIO) came under pressure on Friday, with shares falling 13% after the company announced it would halt development of tebapivat for lower-risk myelodysplastic syndromes (LR-MDS). The decision follows results from a Phase 2b study that failed to achieve the internal criteria required to support further development of the oral pyruvate kinase activator in this indication, representing a setback for the biotech
B of A Securities analyst Greg Harrison maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price target from $41 to $40.
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.1% and the actively trad
David Chang will leave his post after an eight-year run at the cell therapy maker. Elsewhere, a next-generation blood disease drug stumbled and an acquisition yielded an FDA approval for AbbVie.
Results did not meet predefined threshold to support further development in LR-MDS Tebapivat was well tolerated, with no new safety signals observedCAMBRIDGE, Mass., May 29, 2026 (GLOBE NEWSWIRE) -- Agios
Agios wins EU approval for Pyrukynd in adult thalassemia patients, expanding the drug's reach as the only authorized therapy for a broad patient population.
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the European Commission (EC) has
Agios Pharmaceuticals (NASDAQ:AGIO) executives said the company is focused on advancing mitapivat across rare hematologic diseases, highlighting early launch traction in thalassemia and a recently submitted supplemental new drug application for sickle cell disease during a presentation at the 2026 R
Why Agios Pharmaceuticals (AGIO) is on investors’ radar today Agios Pharmaceuticals (AGIO) has drawn investor attention after recent share price moves, with the stock last closing at US$28.73 and showing mixed short term returns over the past week, month and past 3 months. Against this backdrop, investors are weighing the company’s current revenue base in rare disease therapies, its reported loss, and how its value score and other valuation markers line up with expectations for a US$1.7b...
Agios Pharmaceuticals has submitted a supplemental New Drug Application to the FDA seeking accelerated approval of mitapivat for sickle cell disease, supported by Phase 2/3 RISE UP data showing improved hemoglobin levels and reduced hemolysis, with detailed results to be presented at the European Hematology Association Congress in June 2026. A key nuance is that the accelerated pathway hinges on a newly agreed 52-week confirmatory trial focused on lowering transfusion burden, which will be...
Agios Pharmaceuticals has submitted a supplemental New Drug Application to the FDA seeking accelerated approval of mitapivat for sickle cell disease. The filing is backed by positive Phase 3 trial results in sickle cell disease. These Phase 3 data are scheduled for a Plenary Abstracts Session at the upcoming EHA Congress. For investors watching Agios Pharmaceuticals (NasdaqGS:AGIO), this regulatory move comes with the stock trading at $28.42 and a mixed return profile, including a gain of...
AGIO seeks FDA accelerated approval for mitapivat in sickle cell disease after mixed phase III data and a planned confirmatory study.
sNDA submission follows agreement with FDA on confirmatory trial, a requirement of the accelerated approval pathway Confirmatory trial designed to demonstrate clinical benefit of mitapivat on reducing transfusion burden in sickle cell disease CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced the submission of its sup
Detailed results from RISE UP Phase 3 trial of mitapivat in sickle cell disease selected for distinguished Plenary Abstracts Session Company to host investor conference call and webcast during EHA 2026 on Saturday, June 13, at 9:00 a.m. ET (3:00 p.m. CEST) CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that new da
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced the submission of its supplemental New
The company faces competitive pressure from Novo Nordisk, but it's growing sales from its existing approved drugs and has an exciting drug in its pipeline.
Agios shares jump 13% as Q1 revenues surge 138% on Aqvesme launch and Pyrukynd growth, while pipeline advances and SCD filing plans take shape.
Moby summary of Agios Pharmaceuticals, Inc.'s Q1 2026 earnings call
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| AGIO | +4.40% | +0.68% | +8.01% | -8.38% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | +1.43% | +6.40% | +11.45% | -21.07% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 3.36M | $113.72M | 0.00% | Added+8.3% | 2026-03-31 |
| DEShaw | quant | 2.68M | $90.70M | 0.05% | Added+45.9% | 2026-03-31 |
| Wellington | fundamental | 641.5K | $21.70M | 0.00% | Added+7.3% | 2026-03-31 |
| TwoSigma | quant | 251.6K | $8.51M | 0.01% | Trimmed-16.2% | 2026-03-31 |
| FidelityFMR | fundamental | 9.1K | $308.56K | 0.00% | Trimmed-62.5% | 2026-03-31 |
| TRowePrice | fundamental | 298.8K | $10.11K | 0.00% | Trimmed-53.2% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-07-30upcoming | -1.58 | — | — |
| 2026-04-29 | -1.79 | -1.69 | +5.66% |
| 2026-02-12 | -1.94 | -1.85 | +4.88% |
| 2025-10-30 | -1.90 | -1.78 | +6.53% |
| 2025-07-31 | -1.75 | -1.93 | -10.03% |
| 2025-05-01 | -1.76 | -1.55 | +11.93% |
| 2025-02-13 | -1.63 | -1.74 | -6.75% |
| 2024-10-31 | 7.91 | -1.47 | -118.52% |
| 2024-08-01 | -1.61 | -1.69 | -4.86% |
| 2024-05-02 | -1.68 | -1.45 | +13.95% |
| 2024-02-15 | -1.64 | -1.72 | -4.98% |
| 2023-11-02 | -1.64 | -1.64 | -0.15% |
| 2023-08-03 | -1.50 | -1.51 | -0.89% |
| 2023-05-04 | -1.72 | -1.47 | +14.70% |
| 2023-02-23 | -1.53 | -1.66 | -8.42% |
| 2022-11-03 | -1.71 | -1.49 | +12.99% |